Hepalink (Hong Kong) Pharmaceutical Co., Ltd, a subsidiary of Chinese drug maker Shenzhen Hepalink Pharmaceutical Group Co., Ltd, has agreed to make a commitment of $40m to a healthcare fund managed by ORI Capital, according to a company filing with The Stock Exchange of Shenzhen on October 24.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
